Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

Delayed Quote. Delayed  - 09/30 05:35:05 pm
37.225 EUR   -0.37%
11:54a MORPHOSYS : Announces That Its Licensee Janssen Reports Positive Res..
11:44a AD HOC : MorphoSys Announces That Its Licensee Janssen Reports Posit..
09/29 MORPHOSYS : and Galapagos Start First-In-Patient Dosing of IL-17C An..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

MORPHOSYS : AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 07:35am CEST

MorphoSys AG / AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec unit entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.

"We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.

 

 

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:
http://www.morphosys.com/

 

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and Slonomics® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.

 

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

 

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

 

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

 

investors@morphosys.com:
mailto:investors@morphosys.com

 

Press Release:
http://hugin.info/130295/R/1533054/466934.pdf

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1533054
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
11:54a MORPHOSYS : Announces That Its Licensee Janssen Reports Positive Results From A ..
11:44a AD HOC : MorphoSys Announces That Its Licensee Janssen Reports Positive Results ..
09/29 MORPHOSYS : and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR10..
09/27 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
09/23 MORPHOSYS : to Present at Upcoming Investor Conferences
09/19 MORPHOSYS : Lanthio Pharma Expands Management Team
09/12 MORPHOSYS : Appoints Four R&D Experts to its Newly Formed Scientific Advisory Bo..
09/06 MORPHOSYS : Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine ..
08/29 MORPHOSYS : to Present at Upcoming Investor Conferences
08/18 MORPHOSYS : "Anti-CD38 Antibody and Lenalidomide Or Bortezomib for the Treatment..
More news
Sector news : Biotechnology & Medical Research - NEC
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/21 MorphoSys (MPSYY) Presents at Bank of America Merrill Lynch 2016 Global Healt..
08/01 MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2016 Results - Earnings Call Trans..
08/01 MorphoSys AG 2016 Q2 - Results - Earnings Call Slides
08/01 MorphoSys AG reports H1'16 results
05/03 MorphoSys' (MPSYF) CEO Simon Moroney on Q1 2016 Results - Earnings Call Trans..
Advertisement
Financials (€)
Sales 2016 48,7 M
EBIT 2016 -64,2 M
Net income 2016 -51,6 M
Finance 2016 203 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 16,1x
EV / Sales 2017 14,8x
Capitalization 988 M
More Financials
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 61,1 €
Spread / Average Target 64%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-35.43%1 110
INCYTE CORPORATION-13.06%17 727
CELLTRION, INC.--.--%11 289
LONZA GROUP AG13.24%10 108
QUINTILES TRANSNATIONA..18.06%9 650
SEATTLE GENETICS, INC.20.34%7 589
More Results